Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule -- Ignore unavailable to you. Want to Upgrade?

To: jbershad who wrote (240)	6/19/1998 8:34:00 AM
From: Dr. John M. de Castro	Read Replies (3) \| Respond to of 399

You're right that H&Q has had ARQL as a strong buy for months. It has been a focus stock for them. They've had it as their lead presentation at their annual biotechnology conference in January for two straight years. Yet, somehow it got listed yesterday as "Coverage Initiated" biz.yahoo.com This is rediculous. No wonder it had no effect on ARQL's stock price. Vector's downgrade by Mike King is news and appears to have rocked the stock. I hope that we can get more information of his reasons. If it is simply a delay due to the merger and the revenues will be in by year end, then this is a very shortsighted downgrade. Mike King is more astute than that. So, I suspect that there is more to the story. I for one am anxious to hear it. John de C